About
About BioSpecifics Technologies Corp
BioSpecifics Technologies Corp., a biopharmaceutical company, develops an injectable collagenase clostridium histolyticum for various indications in the United States and internationally. The company offers injectable collagenase for the treatment of Dupuytren's contracture and Peyronie's disease under the XIAFLEX and Xiapex brands. It also provides injectable collagenase to treat frozen shoulder, cellulite, canine lipoma, lateral hip fat, plantar fibromatosis, human lipoma, and uterine fibroids. The company has a development and license agreement with Endo Global Ventures. BioSpecifics Technologies Corp. was founded in 1957 and is headquartered in Wilmington, Delaware. As of December 1, 2020, BioSpecifics Technologies Corp. operates as a subsidiary of Endo International plc.
Visit company website
5 years, 4 months ago
BioSpecifics Technologies Corp is currently in a long term uptrend where the price is trading 36.8% above its 200 day moving average.
From a valuation standpoint, the stock is 98.7% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 17.8.
BioSpecifics Technologies Corp's total revenue rose by 19.2% to $11M since the same quarter in the previous year.
Its net income has dropped by 14.1% to $5M since the same quarter in the previous year.
Finally, its free cash flow fell by 65.7% to $2M since the same quarter in the previous year.
Based on the above factors, BioSpecifics Technologies Corp gets an overall score of 3/5.